Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells-Reference-Cited by-同舟云学术

Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells

Published:2009-03 Issue:3 Volume:33 Page:465-473
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

d’Argouges Sandrine,Wissing Sandra,Brandl Christian,Prang Nadja,Lutterbuese Ralf,Kozhich Alex,Suzich JoAnn,Locher Mathias,Kiener Peter,Kufer Peter,Hofmeister Robert,Baeuerle Patrick A.,Bargou Ralf C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. CD20: a regulator of cell-cycle progression of B lymphocytes;Tedder;Immunol Today,1994

2. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma;Hainsworth;J Clin Oncol,2002

3. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation;Colombat;Blood,2001

4. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fcγ receptor FcgammaRIIIa gene;Cartron;Blood,2002

5. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction;Byrd;Blood,2002

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

2. HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors;Molecular Cancer Therapeutics;2024-04-26

3. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?;Clinical and Experimental Immunology;2024-04-20

4. Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia;Pharmaceuticals;2024-03-05

5. Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”;Cancers;2023-10-19